Carbonic anhydrase
Family in Homo sapiens that 2 drugs act on.
- Drugs that act on it: 2
- Approved: 2
- In phases 1 to 3: 0
- Sponsors: 2
- Genes: 12
Who is on it, and how far along
Every drug ChEMBL records acting on CA1, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 2
| Sulthiame | Approved | Shionogi | Small molecule | InhibitorCarbonic anhydrase inhibitor | 2 |
| Ethoxzolamide | Approved | Pfizer | Small molecule | InhibitorCarbonic anhydrase inhibitor | 0 |
| Study of Sulthiame (S-054502) in Participants With Renal Impairment and Matched Healthy Controls | Sulthiame | Phase 1 | Not yet recruiting | Shionogi | Oct 5, 2026 |
| Effect of Sulthiame on EEG in Childhood Epilepsy Syndromes | Sulthiame | — | Recruiting | University Hospital, Angers | Jun 2, 2023 |
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2095180, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets